HLA-C and neoplasm: In the absence of a tumor-associated antigen target (TAA), alternative technologies using antibody-based CARs to mimic T cell receptor (TCR) recognition of specific tumor-neoantigens, such as the complex of BRAFV600E oncoprotein with MHC, could be further investigated (40).